Literature DB >> 8891462

Management of gastrointestinal motility disorders. A practical guide to drug selection and appropriate ancillary measures.

J R Malagelada1, E Distrutti.   

Abstract

The focus of management of gastrointestinal motility disorders should be to improve survival and quality of life. Some motor disorders are annoying, but are compatible with virtually normal activity and carry no significant life risk. Conversely, other motor disorders are highly incapacitating and may shorten life expectancy because of complications and nutritional impairment. Management is based first on establishing the correct diagnosis and prognosis; secondly, on adjusting therapy to the severity of illness; and thirdly, on preventing significant complications. Simple recommendations on appropriate changes in lifestyle and reassurance may suffice in mild cases. Pharmacological therapy and, exceptionally, surgical or nutritional measures may be required in other patients. Generally, pharmacological agents should be directed towards correcting specific pathophysiological abnormalities, but this is not always possible. Symptomatic relief may be achieved on an empirical basis. Long term treatment may often require the combination of different therapeutic approaches either sequentially or simultaneously.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891462     DOI: 10.2165/00003495-199652040-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  86 in total

Review 1.  Current medical therapy for esophageal motility disorders.

Authors:  S R Achem; B E Kolts
Journal:  Am J Med       Date:  1992-05-27       Impact factor: 4.965

2.  Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus.

Authors:  G Bassotti; M Gaburri; B P Imbimbo; C Betti; S Daniotti; M A Pelli; A Morelli
Journal:  Scand J Gastroenterol       Date:  1988-11       Impact factor: 2.423

3.  Histamine H2-antagonists modify gastric emptying in the rat.

Authors:  G Bertaccini; C Scarpignato
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

4.  Erythromycin stimulates gallbladder emptying and motilin release by atropine-sensitive pathways.

Authors:  S Fiorucci; R Bosso; A Morelli
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

5.  Dual effects of cisapride on gastric emptying and antropyloroduodenal motility.

Authors:  R Fraser; M Horowitz; A Maddox; J Dent
Journal:  Am J Physiol       Date:  1993-02

Review 6.  Gastrointestinal motility disorders in scleroderma.

Authors:  R W Sjogren
Journal:  Arthritis Rheum       Date:  1994-09

7.  The surgeon's role in the treatment of chronic intestinal pseudoobstruction.

Authors:  M M Murr; M G Sarr; M Camilleri
Journal:  Am J Gastroenterol       Date:  1995-12       Impact factor: 10.864

8.  Clebopride enhances contractility of the guinea pig stomach by blocking peripheral D2 dopamine receptor and alpha-2 adrenoceptor.

Authors:  K Takeda; K Taniyama; T Kuno; I Sano; T Ishikawa; I Ohmura; C Tanaka
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

9.  Intestinal transplantation at the University of Pittsburgh.

Authors:  S Todo; A Tzakis; J Reyes; K Abu-Elmagd; H Furukawa; B Nour; Z Kadry; J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

10.  Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly.

Authors:  M F Stolk; K J van Erpecum; H P Koppeschaar; M Samsom; A J Smout; L M Akkermans; T L Peeters; G P vanBerge-Henegouwen
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

View more
  3 in total

Review 1.  Xiangshaliujunzi Decoction for the treatment of diabetic gastroparesis: a systematic review.

Authors:  Jia-Xing Tian; Min Li; Jiang-Quan Liao; Wen-Ke Liu; Xiao-Lin Tong
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 2.  Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm.

Authors:  M Storr; H D Allescher; M Classen
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Curcumin improves expression of SCF/c-kit through attenuating oxidative stress and NF-κB activation in gastric tissues of diabetic gastroparesis rats.

Authors:  Qi-Hui Jin; Hong-Xia Shen; Hui Wang; Qi-Yang Shou; Qiang Liu
Journal:  Diabetol Metab Syndr       Date:  2013-03-01       Impact factor: 3.320

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.